Some PD-L1-negative patients also benefit from immunotherapy rechallenge, suggesting that combining PD-L1 with other immune-related biomarkers—such as tumor infiltrating lymphocytes, tumor mutational burdon, or IFN-γ signaling—may improve patient selection. Here, CD274 is linked to neoplasm.